MDD
MCID: DPR016
MIFTS: 63

Depression (MDD)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Depression

MalaCards integrated aliases for Depression:

Name: Depression 25 29 42 62
Depressive Disorder 25 54 71
Major Depressive Disorder 25 71
Unipolar Depression 25 71
Clinical Depression 25 71
Depressive Syndrome 54 71
Major Depression 25 54
Mental Depression 71
Mdd 25

Classifications:



External Ids:

UMLS 71 C0011570 C0011581 C0041696 more

Summaries for Depression

Genetics Home Reference : 25 Depression (also known as major depression or major depressive disorder) is a psychiatric disorder that affects mood, behavior, and overall health. It causes prolonged feelings of sadness, emptiness, or hopelessness, and a loss of interest in activities that were once enjoyed. People with depression may also have changes in appetite (leading to overeating or not eating enough), changes in sleeping patterns (sleeping too much or not being able to sleep), loss of energy, and difficulty concentrating. Although depression is considered primarily a mental health disorder, it can also have physical features including headaches, other unexplained aches and pains, unusually slow or fast movements, and digestive problems. To be diagnosed with depression, an individual must have signs and symptoms nearly every day for at least 2 weeks. However, the features of this condition vary widely. Depression most commonly begins in late adolescence or early adulthood, although it can appear at any age. If untreated, episodes of depression can last for weeks, months, or years, and can go away and come back (recur). Affected individuals may have difficulty functioning in their daily lives, including at school or work. People with depression have a higher risk of substance abuse problems and dying by suicide than the general population. Several health conditions are closely related to depression or have depression as a characteristic feature. These include dysthymia (which has long-lasting signs and symptoms that are similar to, but not as severe as, those of depression), perinatal or postpartum depression (which occurs around or following the birth of a child), seasonal affective disorder (which is triggered by the changing of the seasons), bipolar disorder (which can include both "highs," or manic episodes, and depressive episodes), and generalized anxiety disorder. In people with schizoaffective disorder, depression or another mood disorder occurs together with features of schizophrenia (a brain disorder that affects a person's thinking, sense of self, and perceptions).

MalaCards based summary : Depression, also known as depressive disorder, is related to postpartum depression and atypical depressive disorder, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Depression is BDNF-AS (BDNF Antisense RNA), and among its related pathways/superpathways are Peptide ligand-binding receptors and CREB Pathway. The drugs Valsartan and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and growth/size/body region

MedlinePlus : 42 Depression is a serious medical illness. It's more than just a feeling of being sad or "blue" for a few days. If you are one of the more than 19 million teens and adults in the United States who have depression, the feelings do not go away. They persist and interfere with your everyday life. Symptoms can include Feeling sad or "empty" Loss of interest in favorite activities Overeating, or not wanting to eat at all Not being able to sleep, or sleeping too much Feeling very tired Feeling hopeless, irritable, anxious, or guilty Aches or pains, headaches, cramps, or digestive problems Thoughts of death or suicide Depression is a disorder of the brain. There are a variety of causes, including genetic, biological, environmental, and psychological factors. Depression can happen at any age, but it often begins in teens and young adults. It is much more common in women. Women can also get postpartum depression after the birth of a baby. Some people get seasonal affective disorder in the winter. Depression is one part of bipolar disorder. There are effective treatments for depression, including antidepressants, talk therapy, or both. NIH: National Institute of Mental Health

PubMed Health : 62 About depression: We all feel sad or lethargic every now and then. And we have all felt down or even desperate at some point in our lives. These phases are a normal part of life, and people usually feel better again after a while. Things are different for people who have depression. Their sadness and negative thoughts last longer and overshadow all of their thoughts and actions. Depression can arise without any triggering events or for no apparent reasons. People often feel like they are stuck in a black hole. They feel cheerless, lack motivation and self-confidence, and think of themselves as worthless. This can make it difficult to do everyday things like going to work or studying. Friends, family and hobbies are often neglected. They don't sleep well. Depression can also make family and friends feel worried, anxious and helpless. Often they want to help but don't know how. It's not always easy for them to tell whether it's a passing phase or a serious illness.

Related Diseases for Depression

Diseases related to Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2204)
# Related Disease Score Top Affiliating Genes
1 postpartum depression 34.6 SLC6A4 HTR1A CRH BDNF
2 atypical depressive disorder 33.8 SLC6A4 HTR2C HTR2A HTR1A CRHR1 CRH
3 mental depression 33.6 TPH2 SLC6A4 HTR2C HTR2A HTR1A GRIA1
4 endogenous depression 33.5 SLC6A4 NOS1 HTR2C HTR2A HTR1A CRHR1
5 neurotic disorder 33.4 SLC6A4 HTR2A HTR1A BDNF
6 fibromyalgia 32.8 SLC6A4 HTR2A CRH BDNF
7 major depressive disorder 32.8 TPH2 SLC6A4 NOS1 HTR2C HTR2A HTR1A
8 melancholia 32.7 SLC6A4 HTR2A HTR1A CRH BDNF
9 eating disorder 32.6 SLC6A4 HTR2C HTR2A CRH BDNF
10 gilles de la tourette syndrome 32.4 SLC6A4 HTR2A HTR1A BDNF
11 sleep apnea 32.4 SLC6A4 HTR2C HTR2A BDNF
12 anxiety 32.4 TPH2 SLC6A4 HTR2C HTR2A HTR1A CRHR1
13 alcohol use disorder 32.4 SLC6A4 HTR2C HTR2A HTR1A CRH BDNF
14 sleep disorder 32.3 SLC6A4 HTR2C HTR2A HTR1A BDNF
15 dysthymic disorder 32.2 SLC6A4 HTR2A HTR1A DISC2 CRH BDNF
16 bulimia nervosa 32.2 SLC6A4 HTR2C HTR2A CRH BDNF
17 bipolar i disorder 32.1 TPH2 SLC6A4 HTR2C HTR2A HTR1A BDNF
18 irritable bowel syndrome 32.1 SLC6A4 HTR2A HTR1A CRHR1 CRH BDNF
19 barbiturate dependence 31.9 SLC6A4 GRIA2
20 schizoaffective disorder 31.9 SLC6A4 RELN HTR2A HTR1A DISC2 BDNF
21 migraine with or without aura 1 31.9 SLC6A4 NOS1 HTR2C HTR2A HTR1A CRH
22 obsessive-compulsive disorder 31.7 TPH2 SLC6A4 HTR2C HTR2A HTR1A GRIA2
23 borderline personality disorder 31.7 TPH2 SLC6A4 HTR2C HTR2A HTR1A CRHR1
24 parkinson disease, late-onset 31.7 SLC6A4 NOS1 HTR2C HTR2A HTR1A GRM1
25 acute stress disorder 31.7 SLC6A4 CRHR1 CRH BDNF
26 adjustment disorder 31.5 SLC6A4 HTR2A BDNF
27 agoraphobia 31.5 SLC6A4 HTR2A HTR1A
28 post-traumatic stress disorder 31.5 SLC6A4 HTR2A CRHR1 CRH BDNF
29 generalized anxiety disorder 31.4 SLC6A4 HTR2C HTR2A HTR1A CRHR1 BDNF
30 hypochondriasis 31.3 SLC6A4 HTR2A HTR1A BDNF
31 tobacco addiction 31.3 SLC6A4 HTR2A CRHR1 BDNF
32 somatization disorder 31.2 SLC6A4 HTR2A HTR1A CRH
33 personality disorder 31.1 TPH2 SLC6A4 HTR2C HTR2A HTR1A CRHR1
34 mood disorder 31.1 TPH2 SLC6A4 RELN HTR2C HTR2A HTR1A
35 amnestic disorder 31.1 HTR1A GRIA1 BDNF
36 autism spectrum disorder 31.1 TPH2 SLC6A4 RELN HTR2C HTR2A DISC2
37 sexual disorder 31.0 SLC6A4 NOS1 HTR2C HTR2A HTR1A
38 drug dependence 31.0 SLC6A4 CRHR1 CRH BDNF
39 panic disorder 31.0 TPH2 SLC6A4 HTR2C HTR2A HTR1A CRHR1
40 alcohol dependence 31.0 TPH2 SLC6A4 HTR2C HTR2A HTR1A CRHR1
41 migraine with aura 31.0 SLC6A4 HTR2C HTR2A
42 serotonin syndrome 30.9 SLC6A4 HTR2A HTR1A
43 chronic fatigue syndrome 30.9 TPH2 SLC6A4 HTR2A HTR1A CRHR1 CRH
44 tic disorder 30.9 TPH2 SLC6A4 HTR2A
45 anorexia nervosa 30.9 SLC6A4 HTR2C HTR2A HTR1A CRH BDNF
46 bipolar disorder 30.8 TPH2 SLC6A4 RELN NOS1 HTR2C HTR2A
47 cocaine dependence 30.8 TPH2 SLC6A4 HTR2C HTR2A
48 migraine without aura 30.8 SLC6A4 HTR1A GRIA1
49 oppositional defiant disorder 30.8 TPH2 SLC6A4 DISC2
50 status epilepticus 30.7 GRIA2 GRIA1 BDNF

Graphical network of the top 20 diseases related to Depression:



Diseases related to Depression

Symptoms & Phenotypes for Depression

UMLS symptoms related to Depression:


dejection emotional, depressed reaction, depression aggravated, affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, depressed - symptom

MGI Mouse Phenotypes related to Depression:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BDNF CBLN1 CRH CRHR1 DLG1 GRIA1
2 growth/size/body region MP:0005378 10.27 BDNF CRH DLG1 GRIA1 GRIA2 GRIA3
3 homeostasis/metabolism MP:0005376 10.25 BDNF CRH CRHR1 DLG1 GRIA1 GRIA2
4 nervous system MP:0003631 10.19 BDNF CBLN1 CRH CRHR1 DLG1 GRIA1
5 mortality/aging MP:0010768 10.18 BDNF CRHR1 DLG1 GRIA2 GRIA3 GRID2
6 integument MP:0010771 10.1 BDNF CRH GRIA1 GRIA2 GRIA3 GRM1
7 muscle MP:0005369 9.92 DLG1 GRID2 GRM1 HTR2A HTR2C NOS1
8 no phenotypic analysis MP:0003012 9.9 BDNF CRH CRHR1 DLG1 GRIA1 GRIA2
9 normal MP:0002873 9.61 BDNF CBLN1 CRH CRHR1 GRIA1 GRIA2
10 reproductive system MP:0005389 9.28 BDNF DLG1 GRIA2 GRIA3 GRID2 GRM1

Drugs & Therapeutics for Depression

PubMed Health treatment related to Depression: 62

Many people who have depression find it hard to accept that fact. One possible reason for this is that they are ashamed about having a mental health problem and don't want their friends, family and colleagues to find out. Some people don't want to have treatment as a result. But treatment can often shorten depressive episodes and relieve people's symptoms. There are various treatment options for depression . The main treatments are psychological treatment, such as cognitive behavioral therapy , and/or medication. Which type of treatment is the most appropriate, where it should take place and how long it lasts will depend on several factors, including how severe the person’s depression is, their personal circumstances, and how their symptoms develop over time. People can talk to a therapist about the advantages and disadvantages of the possible treatments, as well as what they expect from treatment and any fears they might have.

Drugs for Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 973)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Prucalopride Approved Phase 4 179474-81-8
4
Norethindrone Approved Phase 4 68-22-4 6230
5
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
6
Methimazole Approved Phase 4 60-56-0 1349907
7
Trimebutine Approved Phase 4 39133-31-8
8
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
9
Loperamide Approved Phase 4 53179-11-6 3955
10
Lactulose Approved Phase 4 4618-18-2 11333
11
Parecoxib Approved Phase 4 198470-84-7
12
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
13
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
14
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
15
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
16
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
17
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
18
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
19
Zinc Approved, Investigational Phase 4 7440-66-6 32051
20
Imipramine Approved Phase 4 50-49-7 3696
21
Lithium carbonate Approved Phase 4 554-13-2
22
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
23
Memantine Approved, Investigational Phase 4 19982-08-2 4054
24
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
25
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
26
leucovorin Approved Phase 4 58-05-9 6006 143
27
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
28
Nortriptyline Approved Phase 4 72-69-5 4543
29
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
30
Ribavirin Approved Phase 4 36791-04-5 37542
31
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
32
Desipramine Approved, Investigational Phase 4 50-47-5 2995
33
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
34
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
35
Isocarboxazid Approved Phase 4 59-63-2 3759
36
Protriptyline Approved Phase 4 438-60-8 4976
37
Trimipramine Approved Phase 4 739-71-9 5584 4055
38
Iloperidone Approved Phase 4 133454-47-4 71360
39
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
40
Levodopa Approved Phase 4 59-92-7 6047
41
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
42
Zolpidem Approved Phase 4 82626-48-0 5732
43
Acetaminophen Approved Phase 4 103-90-2 1983
44
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
45
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
46
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
47
Clonidine Approved Phase 4 4205-90-7 2803
48
Terazosin Approved Phase 4 63590-64-7 5401
49
Prazosin Approved Phase 4 19216-56-9 4893
50
Codeine Approved, Illicit Phase 4 76-57-3 5284371

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
2 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
3 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder Unknown status NCT02051413 Phase 4 Venlafaxine extended release
4 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
5 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
6 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
7 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
8 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
9 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
10 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
11 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
12 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
13 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
14 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
15 A Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Before and After Treatment With Desvenlafaxine Unknown status NCT02859103 Phase 4 Desvenlafaxine
16 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
17 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
18 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
19 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
20 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
21 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
22 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
23 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
24 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
25 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
26 Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
27 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
28 Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
29 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
30 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy - a Monocentric, Double-Blind, Placebo-Controlled Trial Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
31 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
32 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
33 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
34 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
35 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
36 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
37 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
38 Phase 4 Study of Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
39 A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
40 Randomized Evaluation of the Effectiveness of Lithium in Subjects With Treatment-Resistant Depression and Suicide Risk. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial Unknown status NCT00927550 Phase 4 lithium;usual care
41 Collaborative Care for Depressed Elders in China Unknown status NCT01287494 Phase 4 Sertraline
42 Double-Blind Randomised Investigation of Tibolone Alone or in Adjunct to Standard Antidepressant Treatment for Depression in Menopausal Women Unknown status NCT01470092 Phase 4 Tibolone
43 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
44 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
45 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
46 Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT") Unknown status NCT00226642 Phase 4 Sertralin;Placebo
47 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
48 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
49 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
50 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill

Search NIH Clinical Center for Depression

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Genetic Tests for Depression

Genetic tests related to Depression:

# Genetic test Affiliating Genes
1 Depression 29

Anatomical Context for Depression

MalaCards organs/tissues related to Depression:

40
Brain, Heart, Testes, Breast, Cortex, Lung, Prefrontal Cortex

Publications for Depression

Articles related to Depression:

(show top 50) (show all 55000)
# Title Authors PMID Year
1
Advance in Diagnosis of Depressive Disorder. 61 42
31784963 2019
2
Individualized Treatment Strategy for Depressive Disorder. 61 42
31784966 2019
3
Internet-Based Management for Depressive Disorder. 61 42
31784968 2019
4
Association analysis of SIGMAR1 with major depressive disorder and SSRI response. 54 61
20178807 2010
5
High levels of Anti-GAD65 and Anti-Ro52 autoantibodies in a patient with major depressive disorder showing psychomotor disturbance. 54 61
20227114 2010
6
A functional polymorphism in the disrupted-in schizophrenia 1 gene is associated with chronic fatigue syndrome. 54 61
20227423 2010
7
Higher serum tropomyosin-related kinase B protein level in major depression. 54 61
20202475 2010
8
Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. 54 61
20194481 2010
9
Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed. 54 61
19782477 2010
10
Aberrant REST-mediated transcriptional regulation in major depressive disorder. 54 61
19846118 2010
11
Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. 54 61
20350136 2010
12
Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. 54 61
20071037 2010
13
Investigation of an epistastic effect between a set of TAAR6 and HSP-70 genes variations and major mood disorders. 54 61
19582769 2010
14
Translin-associated factor X gene (TSNAX) may be associated with female major depressive disorder in the Japanese population. 54 61
19760522 2010
15
Serum adiponectin and resistin levels in major depressive disorder. 54 61
19694629 2010
16
Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. 54 61
20004363 2010
17
Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population. 54 61
20033742 2010
18
BDNF genotype moderates the relation between physical activity and depressive symptoms. 54 61
20230085 2010
19
The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. 54 61
19778568 2010
20
Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. 54 61
20010318 2010
21
The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). 54 61
19591966 2010
22
Genetic linkage of region containing the CREB1 gene to depressive disorders in families with recurrent, early-onset, major depression: a re-analysis and confirmation of sex-specific effect. 54 61
19517574 2010
23
The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. 54 61
19589373 2010
24
TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. 54 61
19874868 2010
25
Chronic social defeat downregulates the 5-HT1A receptor but not Freud-1 or NUDR in the rat prefrontal cortex. 54 61
20026183 2010
26
Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. 54 61
20016225 2010
27
Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. 54 61
20016223 2010
28
Association study of CREB1 with Major Depressive Disorder and related phenotypes. 54 61
19194961 2009
29
Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. 54 61
19844206 2009
30
Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. 54 61
19996035 2009
31
Sex-specific interaction between MAOA promoter polymorphism and Apo epsilon 2 allele in major depressive disorder in the Chinese population. 54 61
19859025 2009
32
Etiological mechanisms of post-stroke depression: a review. 54 61
19891854 2009
33
Glucocorticoid receptor polymorphisms in major depression. 54 61
19906242 2009
34
Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. 54 61
19576267 2009
35
Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. 54 61
19375869 2009
36
Reduced platelet BDNF level in patients with major depression. 54 61
19371767 2009
37
5-HTT genotype effect on prefrontal-amygdala coupling differs between major depression and controls. 54 61
19387615 2009
38
Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. 54 61
19278673 2009
39
5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. 54 61
19590397 2009
40
The norepinephrine transporter gene modulates the relationship between urban/rural residency and major depressive disorder in a Chinese population. 54 61
19564048 2009
41
Antagonist but not agonist labeling of serotonin-1A receptors is decreased in major depressive disorder. 54 61
19215942 2009
42
Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. 54 61
19272410 2009
43
Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. 54 61
19272758 2009
44
MAOA gene polymorphisms and response to mirtazapine in major depression. 54 61
19382113 2009
45
Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. 54 61
19428704 2009
46
5-HT(1A) receptor function in major depressive disorder. 54 61
19428959 2009
47
Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. 54 61
19183998 2009
48
Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. 54 61
19229839 2009
49
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. 54 61
19200422 2009
50
Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder. 54 61
19166896 2009

Variations for Depression

Expression for Depression

Search GEO for disease gene expression data for Depression.

Pathways for Depression

Pathways related to Depression according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 HTR2C HTR2A HTR1A GRM1 GRID2 GRIA3
2
Show member pathways
13.14 HTR2C HTR2A HTR1A GRM1 GRID2 GRIA3
3
Show member pathways
12.97 NOS1 HTR2C HTR2A GRM1 CRHR1 CRH
4
Show member pathways
12.92 SLC6A4 PICK1 GRM1 GRIA3 GRIA2 GRIA1
5
Show member pathways
12.69 NOS1 GRM1 GRIA3 GRIA2 GRIA1
6
Show member pathways
12.52 NOS1 GRM1 GRIA3 GRIA2 GRIA1 BDNF
7
Show member pathways
12.46 GRM1 GRIA3 GRIA2 GRIA1
8 12.29 TPH2 PICK1 NOS1 HTR1A GRM1 GRIA3
9 12.28 NOS1 GRIA3 GRIA2 GRIA1
10 12.23 HTR1A GRIA3 GRIA2 GRIA1 BDNF
11
Show member pathways
12.21 NOS1 HTR2C HTR2A GRM1
12
Show member pathways
12.13 GRM1 GRIA3 GRIA2 GRIA1
13 12.04 TPH2 SLC6A4 HTR2A HTR1A BDNF
14
Show member pathways
12 GRM1 GRIA3 GRIA1 DLG1
15
Show member pathways
11.95 GRIA3 GRIA2 GRIA1 BDNF
16
Show member pathways
11.93 NOS1 GRIA3 GRIA2 GRIA1
17 11.92 GRIA3 GRIA2 GRIA1 DLG1 BDNF
18
Show member pathways
11.86 HTR2C HTR2A HTR1A
19
Show member pathways
11.8 GRM1 GRIA3 GRIA2 GRIA1
20 11.78 TPH2 SLC6A4 HTR2C HTR2A HTR1A
21 11.75 HTR2C HTR2A GRM1
22
Show member pathways
11.56 PICK1 GRIA3 GRIA2 GRIA1 DLG1
23
Show member pathways
11.41 TPH2 SLC6A4 NOS1
24 11.37 GRIA3 GRIA2 GRIA1